38. A PILOT STUDY TO EVALUATE ANTIBACTERIAL POTENTIALS OF ADVANCED PLATELET-RICH FIBRIN PLUS AGAINST TWO DIFFERENT STRAINS OF STAPHYLOCOCCUS AUREUS

Nguyen Thanh Nhan1, Le Hoang Son1
1 Department of Oral Surgery, Faculty of Dentistry, University of Medicine and Pharmacy, Ho Chi Minh City

Main Article Content

Abstract

platelet-rich fibrin plus (A-PRF+) against two strains of Staphylococcus aureus.


Method: A-PRF+ samples were collected from three volunteers who met the inclusion criteria. The bacterial strains used were methicillin-sensitive Staphylococcus aureus (MSSA, ATCC 6538) and methicillin-resistant Staphylococcus aureus (MRSA, ATCC 33591). Both strains were reactivated following the manufacturer's instructions and prepared at a concentration equivalent to 0.5 McFarland standard for the experiments. Venous blood from each volunteer was collected by a trained nurse and transferred into A-PRF+ and S-PRF tubes. The tubes were centrifuged at 1300 rpm for 8 minutes. Antibacterial activity was preliminarily assessed using three assays: agar diffusion, minimum inhibitory concentration (MIC), and biofilm formation inhibition.


Results: A clear inhibition zone was observed around A-PRF+ clots on agar plates inoculated with MSSA and MRSA, with mean diameters of 0.59 mm and 0.73 mm, respectively. In the MIC assay, A-PRF+ from all three volunteers inhibited both MSSA and MRSA at a 1:4 dilution. In the biofilm inhibition test using a 96-well microplate, the percentage of surface area covered by biofilm after 24-hour incubation in the presence of A-PRF+ was 57.20% for MSSA and 63.54% for MRSA.


Conclusion: Preliminary findings suggest that A-PRF+ exhibits antibacterial potential against both methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus. However, studies with larger sample sizes are necessary to confirm and further characterize the antibacterial efficacy of A-PRF+ against S. aureus.

Article Details

References

[1] Dignam P, Elshafey M, Jeganathan A, Foo M, Park JS, Ratnaweera M. Prevalence and Factors Influencing Post-Operative Complications following Tooth Extraction: A Narrative Review. Int J Dent. 2024;2024:7712829. Epub 2024/05/17. doi: 10.1155/2024/7712829. PubMed PMID: 38756385; PubMed Central PMCID: PMCPMC11098612.
[2] Donkor ES, Kotey FC. Methicillin-Resistant Staphylococcus aureus in the Oral Cavity: Implications for Antibiotic Prophylaxis and Surveillance. Infect Dis (Auckl). 2020;13:1178633720976581. Epub 2021/01/07. doi: 10.1177/1178633720976581. PubMed PMID: 33402829; PubMed Central PMCID: PMCPMC7739134.
[3] Xiang X, Shi P, Zhang P, Shen J, Kang J. Impact of platelet-rich fibrin on mandibular third molar surgery recovery: a systematic review and meta-analysis. BMC Oral Health. 2019;19(1):163. Epub 2019/07/28. doi: 10.1186/s12903-019-0824-3. PubMed PMID: 31345203; PubMed Central PMCID: PMCPMC6659259.
[4] Polak D, Clemer-Shamai N, Shapira L. Incorporating antibiotics into platelet-rich fibrin: A novel antibiotics slow-release biological device. J Clin Periodontol. 2019;46(2):241-7. Epub 2019/01/11. doi: 10.1111/jcpe.13063. PubMed PMID: 30629300.
[5] Feng M, Wang Y, Zhang P, Zhao Q, Yu S, Shen K, et al. Antibacterial effects of platelet-rich fibrin produced by horizontal centrifugation. International Journal of Oral Science. 2020;12(1):32. doi: 10.1038/s41368-020-00099-w.
[6] Jasmine S, A T, Janarthanan K, Krishnamoorthy R, Alshatwi AA. Antimicrobial and antibiofilm potential of injectable platelet rich fibrin—a second-generation platelet concentrate—against biofilm producing oral staphylococcus isolates. Saudi Journal of Biological Sciences. 2020;27(1):41-6. doi: https://doi.org/10.1016/j.sjbs.2019.04.012.
[7] Phuong Tran TT, Vu Pham TA. Effect of advanced and injectable platelet-rich fibrins against Aggregatibacter actinomycetemcomitans in subjects with or without periodontal diseases. J Dent Sci. 2023;18(2):491-6. Epub 2023/04/07. doi: 10.1016/j.jds.2022.09.014. PubMed PMID: 37021261; PubMed Central PMCID: PMCPMC10068356.
[8] Pham TAV, Tran TTP, Luong NTM. Antimicrobial Effect of Platelet-Rich Plasma against Porphyromonas gingivalis. Int J Dent. 2019;2019:7329103. Epub 2019/06/20. doi: 10.1155/2019/7329103. PubMed PMID: 31214262; PubMed Central PMCID: PMCPMC6535835.
[9] Yang LC, Hu SW, Yan M, Yang JJ, Tsou SH, Lin YY. Antimicrobial activity of platelet-rich plasma and other plasma preparations against periodontal pathogens. J Periodontol. 2015;86(2):310-8. Epub 2014/10/28. doi: 10.1902/jop.2014.140373. PubMed PMID: 25345340.